Ethinylestradiol/segesterone acetate

Ethinylestradiol /
segesterone acetate
Combination of
Ethinylestradiol Estrogen
Segesterone acetate Progestogen
Clinical data
Trade names Annovera
Synonyms EE/SGA; EE/SA
Routes of
administration		 Vaginal ring

Ethinylestradiol/segesterone acetate (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains ethinylestradiol, an estrogen, and segesterone acetate, a progestin.[1] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day, and lasts for a duration of one year.[1][2] The medication was developed by TherapeuticsMD and was approved for use in the United States on 10 August 2018.[2]

See also

References

  1. 1 2 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
  2. 1 2 https://ir.therapeuticsmd.com/news-releases/news-release-details/therapeuticsmd-announces-fda-approval-annoveratm-segesterone



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.